"Pfizer and Moderna's Covid Vaccine Windfall Takes a Turn"
TL;DR Summary
Reduced demand and revenue for Covid vaccines from Pfizer and Moderna is not necessarily bad news for the pharmaceutical industry, as it is a result of the industry functioning as designed. Despite the initial surge in share prices and record-breaking sales in 2022, the decrease in demand is a natural consequence of the evolving Covid situation and the need for updated boosters.
Reading Insights
Total Reads
0
Unique Readers
10
Time Saved
1 min
vs 1 min read
Condensed
66%
184 → 62 words
Want the full story? Read the original article
Read on The Wall Street Journal